Your browser doesn't support javascript.
loading
Interactive Data Visualization Tool for Patient-Centered Decision Making in Kidney Cancer.
Shee, Kevin; Pal, Sumanta K; Wells, J Connor; Ruiz-Morales, Jose Manuel; Russell, Kenton; Dudani, Shaan; Choueiri, Toni K; Heng, Daniel Y; Gore, John L; Odisho, Anobel Y.
Afiliação
  • Shee K; Department of Urology, University of California San Francisco, San Francisco, CA.
  • Pal SK; Department of Medical Oncology, City of Hope National Medical Center Duarte, CA.
  • Wells JC; Department of Medical Oncology, Tom Baker Cancer Centre, University of Calgary, Canada.
  • Ruiz-Morales JM; Department of Medical Oncology, Tom Baker Cancer Centre, University of Calgary, Canada.
  • Russell K; Department of Urology, University of California San Francisco, San Francisco, CA.
  • Dudani S; William Osler Health System, Canada.
  • Choueiri TK; Dana-Farber Cancer Institute, Boston, MA.
  • Heng DY; Department of Medical Oncology, Tom Baker Cancer Centre, University of Calgary, Canada.
  • Gore JL; Department of Urology, University of Washington, Seattle, WA.
  • Odisho AY; Department of Urology, University of California San Francisco, San Francisco, CA.
JCO Clin Cancer Inform ; 5: 912-920, 2021 08.
Article em En | MEDLINE | ID: mdl-34464153
ABSTRACT

PURPOSE:

Patients and providers often lack clinical decision tools to enable effective shared decision making. This is especially true in the rapidly changing therapeutic landscape of metastatic kidney cancer. Using the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria, a validated risk prediction tool for patients with metastatic renal cell carcinoma, we created and user-tested a novel interactive visualization for clinical use.

METHODS:

An interactive visualization depicting IMDC criteria was created, with the final version including data for more than 4,500 patients. Usability testing was performed with nonmedical lay-users and medical oncology fellow physicians. Subjects used the tool to calculate median survival times based on IMDC criteria. User confidence was surveyed. An iterative user feedback implementation cycle was completed and informed revision of the tool.

RESULTS:

The tool is available at CloViz-IMDC. Initially, 400 lay-users and 15 physicians completed clinical scenarios and surveys. Cumulative accuracy across scenarios was higher for physicians than lay-users (84% v 74%; P = .03). Eighty-three percent of lay-users and 87% of physicians thought the tool became intuitive with use. Sixty-eight percent of lay-users wanted to use the tool clinically compared with 87% of physicians. After revisions, the updated tool was user-tested with 100 lay-users and 15 physicians. Physicians, but not lay-users, showed significant improvement in accuracy in the updated version of the tool (90% v 67%; P = .008). Seventy-two percent of lay-users and 93% of physicians wanted to use the updated tool in a clinical setting.

CONCLUSION:

A graphical method of interacting with a validated nomogram provides prognosis results that can be used by nonmedical lay-users and physicians, and has the potential for expanded use across many clinical conditions.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Neoplasias Renais Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Humans Idioma: En Revista: JCO Clin Cancer Inform Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Canadá

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Neoplasias Renais Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Humans Idioma: En Revista: JCO Clin Cancer Inform Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Canadá